Bacteria get the headlines. Viruses get the funding. Fungi get ignored. That neglect is starting to cost lives. Candida auris, a drug-resistant yeast first identified in a Japanese patient's ear canal in 2009, has spread to more than 30 countries and kills 30-60% of patients who develop bloodstream infections. Some strains resist all three major classes of antifungal drugs. The CDC labeled it an "urgent threat" in 2019, its highest category. Most people have still never heard of it.

Only four classes of antifungal medications exist. Antibacterial drugs have more than twenty. If a fungal pathogen develops resistance to those four classes, there is no Plan E. We're already seeing strains of Candida auris where Plan A, B, and C have failed.

Why are fungal infections getting worse?

Climate change, increased use of agricultural fungicides, and a growing population of immunocompromised patients are converging to expand the range, resistance, and severity of fungal diseases worldwide. Warming global temperatures are training fungi to survive at higher body temperatures, which was previously the human body's primary defense against fungal infection.

Your body runs at 37 degrees Celsius (98.6 Fahrenheit). Most environmental fungi can't survive that heat, which is why fungal infections in healthy people have historically been limited to skin, nails, and mucosal surfaces. But as average temperatures rise, fungi in soil and water are adapting to higher thermal ranges. A fungus that can tolerate 35 degrees Celsius today may tolerate 37 degrees in a few generations. When it can, it gains access to your bloodstream.

Agricultural fungicide use is another accelerant. Azole fungicides sprayed on crops are chemically related to azole antifungal drugs used in medicine. Aspergillus fumigatus, a common soil mold that infects immunocompromised patients, has developed azole resistance in agricultural areas of the Netherlands, India, and Colombia. Patients arrive at the hospital with infections already resistant to first-line treatment because the fungus evolved resistance in a wheat field.

Immunocompromised populations are expanding. More organ transplant recipients, more cancer patients on chemotherapy, more people living with HIV, more patients on immunosuppressive biologics for autoimmune diseases. These are the populations most vulnerable to invasive fungal infections, and their numbers grow every year.

What is Candida auris and why does it scare epidemiologists?

Candida auris is a multidrug-resistant yeast that colonizes skin, survives on hospital surfaces for weeks, spreads easily between patients, and kills 30-60% of those who develop invasive bloodstream infections. It appeared on three continents simultaneously and independently, which suggests environmental pressure rather than a single origin event.

First identified in 2009, C. auris was reported in hospitals across India, South Africa, Venezuela, and the United States within a decade. By 2023, the US alone had reported over 2,300 clinical cases, with numbers rising 95% year-over-year. Outbreaks hit long-term care facilities and ICUs especially hard, where vulnerable patients and frequent skin-to-surface contact create ideal transmission conditions.

What makes it particularly dangerous:

Where is Valley fever expanding?

Coccidioidomycosis, known as Valley fever, is caused by Coccidioides fungi living in desert soil across the southwestern United States and parts of Mexico and Central and South America. Climate modeling and case data show it expanding northward into areas of California, Utah, Nevada, and Washington state that were previously outside its range.

Valley fever infects about 150,000 people per year in the US, though the majority of cases are mild or asymptomatic. Roughly 5-10% develop serious pulmonary illness, and about 1% develop disseminated disease that can infect bones, joints, and the central nervous system. Disseminated coccidioidomycosis has a mortality rate of approximately 40% without treatment.

The fungus lives in arid soil and becomes airborne during wind events, dust storms, construction, and earthquakes. Arizona and California's Central Valley have historically reported the most cases. But in 2024, Washington state confirmed locally acquired cases in areas where Coccidioides had never been documented. Soil surveys found the fungus in new locations correlated with drought conditions and warming winter temperatures.

For you, this means Valley fever is no longer a disease you only worry about in Phoenix or Bakersfield. If you live in the western US and develop a persistent cough, fever, and fatigue that doesn't respond to antibiotics, mention travel history and soil exposure to your doctor. Valley fever is frequently misdiagnosed as bacterial pneumonia because most physicians outside endemic areas don't think to test for it.

What happened with Aspergillus during COVID?

COVID-associated pulmonary aspergillosis (CAPA) killed an estimated 10-15% of critically ill COVID patients in ICUs during the first two pandemic waves. The virus damaged lung tissue, steroids suppressed the immune response, and Aspergillus fumigatus colonized the wreckage.

Studies from the Netherlands, Belgium, and India reported CAPA rates of 20-35% among mechanically ventilated COVID patients. Many of these Aspergillus infections were azole-resistant, particularly in regions with heavy agricultural fungicide use. Patients already fighting for their lives against a viral pneumonia then faced a secondary fungal infection with limited treatment options.

India experienced an even more dramatic fungal crisis. Mucormycosis (black fungus), caused by Rhizopus and related molds, surged during India's devastating Delta wave in 2021. Over 45,000 cases were reported in a matter of months, many in diabetic patients treated with high-dose steroids.

Mucormycosis invades blood vessels, destroys tissue, and requires aggressive surgical debridement. Many patients lost eyes or portions of their jaw. Mortality ranged from 30-80% depending on the site of infection.

These weren't isolated complications. They revealed how vulnerable the modern medical system is to fungal pathogens when large numbers of immunocompromised patients appear simultaneously.

Why is the antifungal pipeline so thin?

Drug companies have underinvested in antifungal development for decades because fungal cells are eukaryotic, like human cells, making it hard to find drug targets that kill the fungus without harming the patient. Bacteria are prokaryotic. The biological differences between bacteria and humans are large, giving antibiotic developers many unique targets. Fungi share most of their cellular machinery with us.

Four classes of systemic antifungals exist:

  1. Azoles (fluconazole, voriconazole, isavuconazole): Block ergosterol synthesis. Most commonly used. Resistance is growing.
  2. Echinocandins (caspofungin, micafungin, anidulafungin): Block cell wall synthesis. Currently the first-line treatment for Candida auris, but resistance has appeared.
  3. Polyenes (amphotericin B): Binds to ergosterol and punches holes in fungal membranes. Effective but toxic to kidneys. Often called "ampho-terrible" by clinicians for its side effects.
  4. Flucytosine: A nucleoside analog used in combination therapy. Limited standalone use.

Compare that to antibacterials, where you have beta-lactams, aminoglycosides, fluoroquinolones, macrolides, tetracyclines, glycopeptides, carbapenems, and more than a dozen other classes. The fungal treatment arsenal is tiny.

New drugs are in development. Olorofim (targeting a metabolic enzyme unique to molds) and fosmanogepix (blocking cell wall anchoring) both show promise against resistant Aspergillus and Candida species. But even optimistic timelines put widespread availability years away, and a single new drug class doesn't change the fundamental math when resistance moves faster than development.

What should you watch for on PandemicAlarm?

PandemicAlarm tracks fungal outbreaks alongside bacterial and viral events. When you see a fungal event flagged on the map, understand that it likely represents a different kind of threat than a respiratory virus. Fungal outbreaks rarely spread person-to-person through casual contact (Candida auris in hospitals is the notable exception). Most are environmental.

Key signals worth your attention:

Fungal threats don't create the same dramatic outbreak curves as respiratory viruses. They build slowly, resist the few drugs we have, and exploit the gaps in a medical system designed primarily to fight bacteria and viruses. Paying attention to them now, before the next immunocompromising pandemic hands them millions of new hosts, is the definition of early warning.